NASDAQ:MDLN Medline (MDLN) Stock Price, News & Analysis $34.96 +0.49 (+1.41%) As of 09:39 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Medline Stock (NASDAQ:MDLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medline alerts:Sign Up Key Stats Today's Range$34.88▼$34.8850-Day Range$33.19▼$48.2652-Week Range$32.81▼$50.88Volume19,629 shsAverage Volume6.91 million shsMarket Capitalization$45.92 billionP/E RatioN/ADividend YieldN/APrice Target$50.54Consensus RatingModerate Buy Company Overview Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers. In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations. Its offerings typically include direct delivery, customized kit and procedure-packaging services, inventory management programs and value‑added services such as clinical education and operational consulting. These capabilities are aimed at improving clinical workflow and supporting large, complex supply networks. Medline operates through an extensive distribution network and serves customers across multiple geographies, with a primary focus on North American healthcare markets alongside international sales and distribution activity. The company is run by an executive leadership team responsible for its commercial, operational and clinical service lines. As a company listed on the NASDAQ under the symbol MDLN, Medline positions itself as an integrated supplier and supply‑chain partner for the healthcare industry.AI Generated. May Contain Errors. Read More Medline Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreMDLN MarketRank™: Medline scored higher than 75% of companies evaluated by MarketBeat, and ranked 21st out of 87 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMedline has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 1 strong buy rating, 22 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialMedline has a consensus price target of $50.54, representing about 46.6% upside from its current price of $34.47.Amount of Analyst CoverageMedline has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medline's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth9.33% Earnings GrowthEarnings for Medline are expected to grow by 9.33% in the coming year, from $1.50 to $1.64 per share.Price to Earnings Growth RatioMedline has a PEG Ratio of 4.77. PEG Ratios above 1 indicate that a company could be overvalued. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.69% of the float of Medline has been sold short.Short Interest Ratio / Days to CoverMedline has a short interest ratio ("days to cover") of 2.84, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medline has recently increased by 21.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedline does not currently pay a dividend.Dividend GrowthMedline does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.46 News SentimentMedline has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Medline this week, compared to 6 articles on an average week.Search Interest11 people have searched for MDLN on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.MarketBeat Follows10 people have added Medline to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medline insiders have not sold or bought any company stock.Percentage Held by Insiders0.81% of the stock of Medline is held by insiders.Percentage Held by InstitutionsMedline has minimal institutional ownership at this time.Read more about Medline's insider trading history. Receive MDLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medline and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDLN Stock News HeadlinesMedline Inc. (MDLN) Presents at 46th Annual William Blair Growth Stock Conference TranscriptJune 3 at 7:00 PM | seekingalpha.comAnalyst Initiates Buy on Medline, Citing Attractive 2027 EBITDA Valuation, International Expansion, and Limited Impact from FDA Warning LetterJune 3 at 6:50 PM | tipranks.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.June 4 at 1:00 AM | Reagan Gold Group (Ad)Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Medline (MDLN)June 3 at 8:39 AM | theglobeandmail.comJohnson & Johnson Rival Medline Stock (MDLN) Sinks on FDA Warning over Production PracticesJune 2 at 3:50 PM | tipranks.comMedline Completes Major Refinancing and Secondary Share OfferingJune 2 at 8:50 AM | tipranks.comMajor Medline Backers Stage Massive Multi-Billion Dollar Stock ExitJune 1 at 10:30 PM | tipranks.comMedline drops 3.9% as large sponsor secondary and margin concerns weigh on sentimentJune 1 at 1:51 PM | quiverquant.comQSee More Headlines MDLN Stock Analysis - Frequently Asked Questions How have MDLN shares performed this year? Medline's stock was trading at $42.00 on January 1st, 2026. Since then, MDLN shares have decreased by 17.9% and is now trading at $34.47. How were Medline's earnings last quarter? Medline (NASDAQ:MDLN) released its quarterly earnings results on Wednesday, May, 6th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.04. Medline's revenue was up 10.7% compared to the same quarter last year. Read the conference call transcript. When did Medline IPO? Medline (MDLN) raised $7 billion in an initial public offering (IPO) on Wednesday, December 17th 2025. The company issued 248,439,654 shares at $26.00-$30.00 per share. When does Medline's lock-up period expire? Medline's lock-up period expires on Monday, June 15th. Medline had issued 216,034,482 shares in its initial public offering on December 17th. The total size of the offering was $6,264,999,978 based on an initial share price of $29.00. After the expiration of Medline's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. Who are Medline's major shareholders? Medline's top institutional shareholders include Janus Henderson Group PLC (0.87%), WCM Investment Management LLC (0.55%), Healthcare of Ontario Pension Plan Trust Fund (0.38%) and Bessemer Group Inc. (0.27%). Insiders that own company stock include Group Vii S1 LLC Tc, Aggregator Lp Mozart II, Cp Circle Ml Holdco Gp, Llc, Carlyle Group Inc, Mozart Coinvestment Ho Carlyle, Tc Group Cayman Investment Hol, Private Ltd Gic, Andrew J Mills, Charles N Mills and Hellman & Friedman Capital Par. View institutional ownership trends. How do I buy shares of Medline? Shares of MDLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/06/2026Today6/04/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/09/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Surgical, Medical, And Dental Instruments And Supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:MDLN CIK2046386 WebN/A Phone(847) 949-3000FaxN/AEmployees43,000Year Founded1966Price Target and Rating Average Price Target for Medline$50.54 High Price Target$62.00 Low Price Target$40.00 Potential Upside/Downside+46.6%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage29 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E Ratio22.98 P/E Growth4.77Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$28.43 billion Price / Sales1.59 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,313,690,000Free Float1,303,047,000Market Cap$45.28 billion OptionableN/A BetaN/A Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:MDLN) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredThe SpaceX S-1 changes everythingSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medline Please log in to your account or sign up in order to add this asset to your watchlist. Share Medline With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
